Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer Ingelheim's commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada.
Merz delivers double-digit growth in strategic business areas
- Details
- Category: Business
Merz, a global leader in aesthetics and neurotoxins, showed substantial growth across both of its strategic focus areas at the end of its most recently completed fiscal year 2017/18. Merz's aesthetics and specialty neurology businesses both increased by 19 percent versus prior year, excluding foreign exchange impact. Together, these two areas now account for 67 percent of the company's healthcare revenue.
The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
- Details
- Category: Pfizer
In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for the Cancer Community (SPARC): Metastatic Breast Cancer (MBC) Challenge: their pioneering grants initiative designed to
Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts. The new building will span 145,000 square feet, offering new laboratory and collaborative working space to accommodate approximately 400 new and current R&D employees focused on advancing science in oncology, immuno-oncology and immunology.
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.
Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
- Details
- Category: AstraZeneca
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
- Details
- Category: Pfizer
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
More Pharma News ...
- Merck Granted U.S. Patent for novel combination of Artificial Intelligence and Blockchain Technology
- Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain
- Amgen receives NMPA approval for Repatha® (evolocumab) In China to reduce the risk of cardiovascular events
- Merck and Tencent announce collaboration on intelligent digital healthcare services in China
- A healthy 2019: Four paws for more relaxation and exercise
- FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
- Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab)